Researchers investigated the proteins associated with ankylosing spondylitis (AS) and the potential proteins that may predict patient treatment response to adalimumab in AS.
Researchers reviewed the incidence and determinants of depression and/or anxiety in patients with ankylosing spondylitis.
Researchers described the efficacy of tofacitinib in reducing pain in patients with inflammatory rheumatic and musculoskeletal diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
The role of mechanoinflammation in the pathogenesis of psoriatic disease and the presence of entheseal lesions as predictors of the onset of clinical joint disease gain support in a new study.
![The contribution of the HLA gene alone to RA heritability has been estimated to be 11% to 37%. [1] Other genes, such as PTPN22, STAT4, CTLA4, TRAF1, PADI4, IRF5, FCRL3, TNFIP3, TNF-α, miRNAs, CD28, CD40, and TYK2 have been associated with susceptibility to, severity of, activity of, and treatment response to RA. [1]](https://1fxghyessyy2gaob23ygwzph-wpengine.netdna-ssl.com/wp-content/uploads/sites/18/2019/01/thinkstockphotos53747224411_1010913-544x306.jpg)
Researchers investigated serum microRNA levels in PsA and assessed the signature in therapeutic responder vs nonresponder patients with PsA.
Researchers explored the incidence rates of hepatobiliary events in the first 6 months of routine treatment with the biosimilar etanercept or an originator drug in inflammatory joint disease.
Researchers compared definitions of high disease activity according to the ASDAS and BASDAI criteria in selecting patients for treatment with biologic disease-modifying antirheumatic drugs.
Researchers assessed the incidence of isotretinoin-triggered axial spondyloarthropathy in acne vulgaris patients based on clinical features and MRI findings and examined clinical and radiologic outcomes after drug withdrawal.
In this case study presented at ACTRIMS 2020, researchers reported on data from a patient with Crohn disease and ankylosing spondylitis who developed autoimmune encephalitis while receiving infliximab.
Recently released guidelines from Japan outline the factors that may influence the choice of biologic agents for treatment in patients with psoriasis.
